Aim Immunotech Stock Alpha and Beta Analysis
| AIM Stock | USD 0.20 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as AIM ImmunoTech. It also helps investors analyze the systematic and unsystematic risks associated with investing in AIM ImmunoTech over a specified time horizon. Remember, high AIM ImmunoTech's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to AIM ImmunoTech's market risk premium analysis include:
Beta (0.02) | Alpha (0.26) | Risk 5.45 | Sharpe Ratio (0.05) | Expected Return (0.27) |
AIM ImmunoTech Quarterly Cash And Equivalents |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
AIM |
AIM ImmunoTech Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. AIM ImmunoTech market risk premium is the additional return an investor will receive from holding AIM ImmunoTech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AIM ImmunoTech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate AIM ImmunoTech's performance over market.| α | -0.26 | β | -0.02 |
AIM ImmunoTech expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of AIM ImmunoTech's Buy-and-hold return. Our buy-and-hold chart shows how AIM ImmunoTech performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.AIM ImmunoTech Market Price Analysis
Market price analysis indicators help investors to evaluate how AIM ImmunoTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading AIM ImmunoTech shares will generate the highest return on investment. By understating and applying AIM ImmunoTech stock market price indicators, traders can identify AIM ImmunoTech position entry and exit signals to maximize returns.
AIM ImmunoTech Return and Market Media
The median price of AIM ImmunoTech for the period between Sun, Nov 3, 2024 and Sat, Feb 1, 2025 is 0.22 with a coefficient of variation of 10.22. The daily time series for the period is distributed with a sample standard deviation of 0.02, arithmetic mean of 0.22, and mean deviation of 0.02. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Thomas Equels of 300000 shares of AIM ImmunoTech at 0.47 subject to Rule 16b-3 | 11/08/2024 |
2 | Kellner Group Urges Stockholders of AIM Immunotech to VoteGold | 11/19/2024 |
3 | AIM Menandatangani Perjanjian Penting 5 Tahun dengan Central European Media Enterprises | 12/04/2024 |
4 | Blend Positioned in Leaders Quadrant in AIM Researchs Top Generative AI Services Providers 2024 Report | 12/09/2024 |
5 | Anthony Abrahams Buys Handful Of Shares In Ai-Media Technologies | 12/10/2024 |
6 | AIMs Clinical Strategy Under Incumbent Board Has Totally Failed | 12/11/2024 |
7 | Anthony Abrahams Buys 250,000 Shares of Ai-Media Technologies Limited Stock | 12/12/2024 |
8 | Acquisition by Bryan Nancy of 24452 shares of AIM ImmunoTech at 0.213 subject to Rule 16b-3 | 12/13/2024 |
9 | AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting | 12/17/2024 |
10 | Disposition of 4580 shares by William Mitchell of AIM ImmunoTech at 0.193 subject to Rule 16b-3 | 12/19/2024 |
11 | Ai-Media Technologies Limited Insider Buys A250,312.50 in Stock | 12/23/2024 |
12 | Acquisition by William Mitchell of 26305 shares of AIM ImmunoTech at 0.198 subject to Rule 16b-3 | 12/31/2024 |
13 | Acquisition by Stewart Appelrouth of 1136 shares of AIM ImmunoTech at 16.72 subject to Rule 16b-3 | 01/08/2025 |
14 | Truv Integrates with Freddie Mac AIM Check API | 01/14/2025 |
15 | AIM ImmunoTech Upgraded to Strong Buy What Does It Mean for the Stock | 01/17/2025 |
About AIM ImmunoTech Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including AIM or other stocks. Alpha measures the amount that position in AIM ImmunoTech has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 4.3K | 2.1K | 1.9K | 2.0K | PTB Ratio | 0.39 | 2.09 | 2.4 | 2.28 |
AIM ImmunoTech Upcoming Company Events
As portrayed in its financial statements, the presentation of AIM ImmunoTech's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AIM ImmunoTech's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of AIM ImmunoTech's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of AIM ImmunoTech. Please utilize our Beneish M Score to check the likelihood of AIM ImmunoTech's management manipulating its earnings.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with AIM ImmunoTech
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out AIM ImmunoTech Backtesting, AIM ImmunoTech Valuation, AIM ImmunoTech Correlation, AIM ImmunoTech Hype Analysis, AIM ImmunoTech Volatility, AIM ImmunoTech History and analyze AIM ImmunoTech Performance. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
AIM ImmunoTech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.